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 tumor-homing peptide, F3, selectively binds to
endothelial cells in tumor blood vessels and to tumor
cells. Here, we show that the cell surface molecule
recognized by F3 is nucleolin. Nucleolin speciﬁcally
bound to an F3 peptide afﬁnity matrix from extracts of
cultured breast carcinoma cells. Antibodies and cell surface
biotin labeling revealed nucleolin at the surface of actively
growing cells, and these cells bound and internalized
fluorescein-conjugated F3 peptide, transporting it into
the nucleus. In contrast, nucleolin was exclusively nuclear
A 
 
in serum-starved cells, and F3 did not bind to these cells.
The binding and subsequent internalization of F3 were
blocked by an antinucleolin antibody. Like the F3 peptide,
intravenously injected antinucleolin antibodies selectively
accumulated in tumor vessels and in angiogenic vessels of
implanted “matrigel” plugs. These results show that cell
surface nucleolin is a speciﬁc marker of angiogenic endo-
thelial cells within the vasculature. It may be a useful target
 
molecule for diagnostic tests and drug delivery applications.
 
Introduction
 
Tumor growth is critically dependent on angiogenesis,
which is the sprouting of new blood vessels from existing
ones (Hanahan and Folkman, 1996). Angiogenic vessels differ
from normal vessels in their morphological and molecular
characteristics. The molecular markers of angiogenic vessels
include endothelial growth factor receptors, integrins,
proteolytic enzymes, and extracellular matrix components
(Ruoslahti, 2002), as well as membrane proteins of unknown
function (St Croix et al., 2000; Christian et al., 2001a). A
specific marker for tumor lymphatics has also been described
previously (Laakkonen et al., 2002).
The molecular markers that distinguish tumor vasculature
from that of normal tissues are important in a number of
ways. Many of the molecules that are selectively expressed in
tumor blood vessels play a functional role in development
and maintenance of new blood vessels. Examples include
endothelial cell growth factor receptors and integrins (Eliceiri
and Cheresh, 1999; Ferrara and Alitalo, 1999; Hynes,
2002), matrix metalloproteases (Brooks et al., 1998; Bergers
et al., 2000), and aminopeptidase N (Pasqualini et al., 2000).
Blocking the function of these proteins inhibits angiogenesis.
Furthermore, these and other molecules selectively expressed
in tumor vasculature can be made use of in targeting diagnostic
and therapeutic agents in tumors (Arap et al., 1998; Nilsson
et al., 2001; El-Sheikh et al., 2002; Hood et al., 2002).
The identification of additional tumor blood vessel markers
helps in the understanding of angiogenesis and could be useful
for tumor targeting. We set out to identify the molecule,
“receptor,” that is recognized by a tumor-homing peptide
recently identified by our laboratory. This peptide, F3,
was discovered in a screening procedure that used a phage-
displayed cDNA library and combined ex vivo screening on
cell suspensions prepared from mouse bone marrow and in
vivo screening for tumor homing. F3 is a 34–amino acid
fragment of a high mobility group protein, HMG2N
(Porkka et al., 2002). F3 homes to the vasculature of various
types of tumors by binding to the endothelial cells. F3 also
binds to a subpopulation of bone marrow cells that may be
precursors for endothelial cells. In some tumors, the F3
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peptide also recognizes the tumor cells. A striking property
of the F3 peptide is that it is internalized by its specific target
cells and transported to the nucleus.
We have now identified cell surface–expressed nucleolin
as the receptor for F3 on tumor cells and angiogenic endo-
thelial cells. Cell surface nucleolin expression is a novel an-
giogenesis marker. It provides a tool for studying tumor an-
giogenesis, including the contribution of precursor cells to
this process, and for targeting drugs into tumors.
 
Results
 
Nucleolin binds to F3 in affinity chromatography
 
The F3 peptide binds to and accumulates within both tu-
mor endothelial cells and tumor cells in vivo (Porkka et al.,
2002). Because F3 also binds to cultured tumor cells such as
the human breast carcinoma cell line MDA-MB-435, we de-
cided to use this cell line to identify a receptor for F3. Affin-
ity chromatography of MDA-MB-435 cell extracts on an F3
peptide affinity matrix revealed a major F3-binding band at
a molecular mass of 110 kD and several bands in the 20-kD
range that did not bind to a control peptide matrix (Fig. 1
A). Mass spectrometry analysis indicated that the 110-kD
band is nucleolin. Although the calculated mass of nucleolin
is 76 kD, it migrates at 110 kD in SDS-PAGE, most likely
because of posttranslational modifications and high content
of negatively charged amino acids in the NH
 
2
 
-terminal re-
gion of the protein (Harms et al., 2001). The 20-kD range
bands were identified as various histones.
The identification of the 110-kD protein as nucleolin was
confirmed by immunoblotting. A monoclonal antinucleolin
antibody, MS-3, revealed a major 110-kD band and faint
lower molecular mass bands in the F3-bound material (Fig.
1 B, a). These bands were not present in eluates from the
control peptide matrix. The faint bands are probably frag-
ments of nucleolin, as they aligned with some of the several
lower molecular mass bands detected by the antibody in a
whole cell extract. These results show that the F3 peptide
can specifically interact with nucleolin, suggesting nucleolin
as a candidate receptor for F3.
We prepared antisera against nucleolin by immunizing
rabbits with two different synthetic peptides from the hu-
man nucleolin sequence. Affinity-purified antibodies recog-
nized a band that aligned with the 110-kD nucleolin band
defined by the MS-3 antibody (Fig. 1 B, b). Like MS-3, the
rabbit antibodies also detected smaller molecular mass bands
that presumably represent nucleolin fragments. As expected,
based on the fact that the immunizing peptides came from
different regions of the nucleolin molecule, the sets of minor
bands detected by each antibody did not overlap. Immuno-
blotting showed that the NCL3 antibody also recognizes a
110-kD protein in extracts of mouse cells. (Fig. 1 B, c).
 
Nucleolin is expressed at the cell surface
 
To serve as an F3 receptor, nucleolin would have to be
present at the cell surface. Nucleolin is primarily known as a
nuclear and cytoplasmic protein, but recent studies have
shown that a cell surface form of nucleolin also exists (Said
et al., 2002; Sinclair and O’Brien, 2002). To determine if
F3-binding nucleolin in the MDA-MB-435 cells is ex-
pressed at the cell surface, exponentially growing cells were
biotinylated with a cell-impermeable biotin reagent, and cell
extracts were subjected to affinity chromatography on im-
mobilized F3. Two biotinylated bands at 110 and 75 kD
specifically bound to F3 (Fig. 2 A, a). The surface biotin-
ylated 75-kD band was stronger than the 110-kD band,
whereas the opposite was true in the affinity chromatogra-
phy, possibly because the cell surface expression or accessi-
bility to biotinylation may be different for the two forms.
Notably, the histones that bound to the F3 matrix from the
cell extract did not become biotin-labeled in intact cells, but
were the most prominent F3-binding bands from cell sur-
face-biotinylated serum-starved cultures, which contain
many dead cells (Fig. 2 A, b). No nucleolin band was detect-
able in the serum-starved cells, suggesting a lack of cell sur-
face nucleolin expression.
Nucleolin was also detected at the cell surface of growing
MDA-MB-435 in FACS
 
®
 
 analysis using antibodies. Both the
polyclonal NCL3 and monoclonal MS-3 antibodies bound to
MDA-MB-435 cells, producing a distinct shift of the fluores-
cence peak relative to control IgG and nonsurface reactive an-
tibody, respectively. That result was consistent in repeated ex-
periments (Fig. 2 B, a and b). Gating for cells that were
negative for propidium iodide uptake showed that the antinu-
cleolin-positive cells were alive and their cell membranes were
intact. We used the polyclonal antibody, which gave a stron-
ger signal with the MDA-MB-435 cells than the monoclonal,
to test cultured human umbilical vein endothelial cells (HU-
VECs) for cell surface nucleolin. A small shift in the fluores-
cence peak was observed (Fig. 2 B, c). These results show that
nucleolin is expressed on the surface of the MDA-MB-435
Figure 1. Nucleolin binds to immobilized F3 peptide. (A) SDS gel 
electrophoresis of Coomassie blue–stained proteins isolated from 
MDA-MB-435 cell extracts on F3 affinity matrix (F3) or control 
peptide matrix (Control). The arrow indicates a specific 110-kD 
band, which was identified as nucleolin by mass spectroscopy. 
(B) Immunoblotting of eluates from F3 and control affinity matrices 
with a monoclonal mouse antinucleolin antibody (a); immunoblotting 
of MDA-MB-435 cell extracts with polyclonal rabbit antinucleolin 
antibodies NCL2 and NCL3 (b); immunoblotting of extracts generated 
from the human cell line C8161 and the mouse cell line 4T1 with 
NCL3 (c). The F3 bound material (a, F3) contains full-length 
nucleolin and a faintly staining 75-kD band. In the original cell 
extract (a, Extract), the antibody recognizes full-length nucleolin 
at 110 kD, along with several faster migrating bands (presumably 
nucleolin fragments), including one at 75 kD. No antinucleolin 
reactive bands are detected in eluates from the control matrix 
(a, Control). Affinity-purified polyclonal antibodies NCL2 and NCL3 
recognize a band that aligns with the 110-kD nucleolin band in human 
extracts, and NCL3 crossreacts with mouse nucleolin (c, Mouse). 
Both antibodies also detect smaller bands that presumably represent 
nucleolin fragments. 
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cells and that HUVECs may also express some cell surface nu-
cleolin. Because the presence of many dead cells prevented a
FACS
 
®
 
 analysis on serum-starved MDA-MB-435 cells, we
used immunostaining to study their subcellular nucleolin dis-
tribution. The NCL3 antibody stained the surface of MDA-
MB-435 cells when the cells were actively growing, but there
was no surface staining of these cells after they were rendered
stationary by serum withdrawal (Fig. 3). Nuclear nucleolin
was detected in permeabilized cells under both conditions.
These results agree with the cell surface biotinylation data
shown in Fig. 2 and suggest that cell surface expression of nu-
cleolin is a characteristic of actively growing cells.
 
Antinucleolin antibodies inhibit internalization 
of F3 by cells
 
Nucleolin has been reported to shuttle between the cytoplasm
and the nucleus (Shibata et al., 2002) and between the cell
surface and the nucleus (Said et al., 2002). We used antibod-
ies to study whether nucleolin is involved in the internaliza-
tion and nuclear transport of F3. As shown previously
(Porkka et al., 2002), fluorescein-labeled F3 was taken up by
the MDA-MB-435 cells and localized in the cytoplasm and
nucleus of 100% of the cells (Fig. 4, a–c). Coincubation of
the cells with the NCL3 antibody inhibited the appearance of
F3 in the cytoplasm and nucleus of the cells (Fig. 4, e–g). In-
stead, the antibody was internalized into the MDA-MB-435
cells and transported into the nucleus. NCL2, although it
bound to the MDA-MB-435 cells, was not internalized and
did not inhibit the cytoplasmic and nuclear localization of F3
(Fig. 4, i–k). Neither antibody affected the internalization of
the cell-penetrating peptide from the Tat protein (Fig. 4, d, h,
and l). These results indicate that F3 binds to cells and is in-
ternalized by them in a nucleolin-dependent manner that in-
volves the NH
 
2
 
-terminal acidic domain of nucleolin.
 
Internalization of the F3 peptide into cultured cells 
is independent of heparan sulfates
 
Next, we determined whether glycosaminoglycans play a role
in the internalization of F3 into cells. The F3 peptide is a
highly basic peptide and, as such, has an affinity for negatively
charged glycosaminoglycans. Previous studies have shown that
binding to heparan sulfates can be sufficient for the internaliza-
tion of a heparan sulfate–binding protein (Roghani and Mos-
Figure 3. Subcellular distribution of nucleolin in dividing and 
stationary cells. MDA-MB-435 cells were cultured in standard culture 
media (a and c) or in media lacking serum (b and d). Nucleolin was 
detected using polyclonal NCL3 antibody in fixed cells without 
permeabilizing the cells (a and b) or after permeabilization with 
Triton X-100 (c and d). Nucleolin appears both on the surface and 
in the nuclei of the actively growing cells cultured in the standard 
media, but is exclusively nuclear in serum-starved cells.
Figure 2. Cell surface expression of nu-
cleolin. (A) F3 affinity chromatography of 
biotin-labeled proteins solubilized from cell 
surface–biotinylated MDA-MB-435 cells. F3 
specifically binds streptavidin-reactive bands 
at 110 (arrow) and 75 kD in nonstarved 
cells (a). These bands are not detectable in serum-starved cells, but a set of low molecular mass bands is prominent (b, arrow). (B) FACS
® 
analysis of antibody binding to MDA-MB-435 cells (a and b) and HUVECs (c). Propidium iodide–negative (living) cells were gated for the 
analysis. Polyclonal antinucleolin NCL3 (a and c) and monoclonal antinucleolin antibody MS-3 (b) cause a shift of the FACS
® peak compared 
with controls (rabbit IgG and an isotype-matched monoclonal antibody with an unrelated specificity, respectively), indicating cell surface 
expression of nucleolin on the MDA-MB-435 and HUVECs. A positive control, an anti– 3 integrin, gives a strong shift, reflecting a high cell 
surface expression of this integrin subunit in both types of cells. 
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catelli, 1992). CHO cells that produce no glycosaminoglycans
because of a mutated xylosyl transferase gene (pgsA-745 cells;
Esko et al., 1985) internalized fluorescein-conjugated F3 and
transported it into the nucleus as efficiently as the wild-type
cells (Fig. 5). Neither cell type internalized a fluorescein-conju-
gated control peptide. Thus, glycosaminoglycans do not seem
to be involved in the uptake of the F3 peptide into cells.
 
Circulating antinucleolin antibodies selectively 
localize in angiogenic blood vessels
 
The F3 peptide, when expressed on the surface of phage, or
labeled with fluorescein or quantum dots, selectively homes
to tumor blood vessels and vessels in a matrigel angiogenesis
Figure 4. Antinucleolin antibodies 
inhibit F3 internalization by cells. 
Exponentially growing MDA-MB-435 
cells were incubated with 1  M FITC-F3 
or FITC-Tat peptide for 2 h at 37 C. 
FITC-F3 is internalized and transported 
into the nucleus (a, FITC-F3, green; b, red 
channel; c, merge). Coincubation with 
antinucleolin antibody NCL3 inhibits the 
cellular uptake and subsequent nuclear 
transport of the peptide (e, F3-FITC, green; 
f, NCL3, red; g, merge). NCL2 has no 
influence on uptake of F3 (i, F3-FITC, 
green; j, NCL2, red; k, merge). Internaliza-
tion of FITC-Tat peptide (d) is not affected 
by NCL3 (h) or NCL2 (l). The antibodies 
were detected with Alexa-594 anti–rabbit 
IgG (red). Nuclei were stained with DAPI 
(blue). The images were obtained by 
confocal microscopy. Bars, 10  m.
Figure 5. Glycosaminoglycan-deficient cells bind and internalize 
F3. FITC-F3 is internalized by the glycosaminoglycan-deficient 
pgsA-745 cells and transported into the nucleus. (a) pgsA-745 cells 
incubated with FITC-F3 and stained with DAPI to visualize the nuclei. 
(b and c) The same field as in panel a viewed separately for the F3 
fluorescence (b) or the nuclear DAPI staining (c). (d) A FITC-labeled 
control peptide is not internalized by the pgsA-745 cells. The images 
were obtained by confocal microscopy. Bars, 10  m.
Figure 6. Intravenously injected antinucleolin antibody accumulates 
in tumor blood vessels. An affinity-purified rabbit antinucleolin 
antibody (NCL3) was injected into the tail vein of mice bearing MDA-
MB-435 xenograft tumors. The tumor and various organs were 
removed 1 h after the injection, sectioned, and examined for the 
presence of rabbit IgG using Alexa-594 anti–rabbit IgG (red). Blood 
vessels were stained with anti-CD31 antibody (green), and nuclei 
were counterstained with DAPI (blue). The antinucleolin antibody 
has bound to tumor blood vessels (a and b), but is not seen in the 
skin (c). Rabbit IgG injected similarly as a control does not bind to 
tumor blood vessels (d). 
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model but not to normal blood vessels. (Akerman et al.,
2002; Porkka et al., 2002; Joyce et al., 2003).
To determine whether antinucleolin would similarly accu-
mulate in tumor vessels and/or tumor cells, we intravenously
injected the NCL3 antibody into mice bearing MDA-MB-
435 tumors. Tissues collected 60 min after injection showed
selective accumulation of the antibody in tumor blood ves-
sels (Fig. 6, a and b). No antibody was detected in associa-
tion with the tumor cells. About 70% of the tumor vessels
were positive for the antibody, whereas no positive vessels
were seen in the blood vessels of the normal tissues tested
(skin and lung; shown for skin subcutaneous tissue in Fig. 6,
c). Purified rabbit IgG, injected as a control, was not de-
tected in tumor blood vessels (Fig. 6, d).
Next, we examined the binding of antinucleolin antibod-
ies to angiogenic blood vessels in a nonmalignant tissue
(matrigel plugs impregnated with basic FGF as an angiogen-
esis inducer). Intravenously injected NCL3 antibodies selec-
tively accumulated in 70% of the blood vessels of subcutane-
ously implanted matrigel plugs (Fig. 7, a). Control IgG was
not detectable in the matrigel plug vessels (Fig. 7, e), and
NCL3 was not detectable in the blood vessels of various con-
trol organs (Fig. 7, b–d). Thus, nucleolin appears to be selec-
tively expressed on the cell surface of angiogenic blood ves-
sels but not on blood vessels of other tissues in vivo.
 
Discussion
 
Here, we show that the tumor-homing F3 peptide, which
binds to and is internalized by endothelial and tumor cells
(Porkka et al., 2002), interacts with nucleolin. We also show
that antinucleolin antibodies detect nucleolin at the surface
of cultured tumor cells and endothelial cells of angiogenic
vessels in vivo. These results support the previously proposed
role for nucleolin as a shuttle molecule between the nucleus
and the cell surface, and they define cell surface nucleolin as
a novel vascular marker for angiogenic endothelium.
Several approaches were used to identify the binding mol-
ecule for the F3 peptide as nucleolin. First, nucleolin and
histones were identified as the main cellular proteins that
specifically bound to immobilized F3 peptide. Cell surface
labeling indicated that the bound nucleolin was derived
from the surface of intact cells, whereas the histones were
not labeled and, therefore, likely originated from dead cells.
Second, inhibition of F3 uptake into cultured cells by an an-
tinucleolin antibody that is internalized into the nucleus
provides additional evidence for the specificity of the F3–
nucleolin interaction and its occurrence in intact cells.
Third, the specific binding of injected antinucleolin anti-
bodies to tumor blood vessels extends the association of F3
binding and cell surface nucleolin expression to an in vivo
animal model.
The nucleolin polypeptide consists of a negatively charged
NH
 
2
 
-terminal domain, an RNA-binding domain, and a
COOH-terminal domain rich in RGG motifs. The main
functions of nucleolin relate to rRNA maturation and ribo-
some assembly (Ginisty et al., 1999; Srivastava and Pollard,
1999). Although nucleolin was originally described as a nu-
clear and cytoplasmic protein, a number of studies show that
it can also be expressed at the cell surface (Deng et al., 1996;
Larrucea et al., 1998; Said et al., 2002; Sinclair and O’Brien,
2002). Recent results also ascribe additional functions to nu-
cleolin as a shuttle protein between the cytoplasm and the
nucleus (Borer et al., 1989; Yu et al., 1998), and between
the cell surface and the nucleus (Schmidt-Zachmann and
Nigg, 1993; Said et al., 2002; Shibata et al., 2002). The lo-
calization of nucleolin within the cell may be regulated by
phosphorylation of its NH
 
2
 
 terminus (Schwab and Dreyer,
1997). Our results provide additional evidence for the cell
surface localization and shuttle function of nucleolin.
The expression of nucleolin at the cell surface seems to cor-
relate with growth and metabolic activity of cells. Both the
uptake of the F3 peptide and the staining of intact cells with
antinucleolin antibodies were suppressed in serum-starved
cells. This may be a proliferation-related effect. An associa-
tion of cell surface nucleolin expression with cell proliferation
in vitro has been described previously (Hovanessian et al.,
2000). Other factors besides proliferation may contribute to
the regulation of cell surface nucleolin expression. We found
only modest levels of cell surface nucleolin on actively prolif-
Figure 7. Cell surface nucleolin is expressed in angiogenic blood vessels. Balb/c nu/nu mice were subcutaneously injected with matrigel 
supplemented with bFGF. 8 d later, an antinucleolin antibody (NCL3) or control IgG was injected into the tail vein of the mice. The matrigel 
plugs were removed 1 h after the injection, sectioned, and examined for the presence of rabbit IgG using Alexa-594 anti–rabbit IgG (red). 
Blood vessels were stained with anti-CD31 antibody (green), and nuclei were counterstained with DAPI (blue). The injected NCL3 colocalizes 
the blood vessel staining in the matrigel plugs (a), but no injected rabbit IgG is detected in the plugs (e). No specific NCL3 accumulation over 
the IgG control is seen in any of the tissues examined: b and f, skin; c and g, heart; or d and h, brain. b–d, NCL3; f–h, IgG.  
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erating endothelial cells in vitro, whereas antinucleolin bind-
ing to angiogenic endothelium was readily detectable in vivo.
The differentiation state of the cells may be a factor contrib-
uting to nucleolin regulation, as cultured human leukemia-
60 cells induced to differentiate into nonproliferating macro-
phages lose their ability to bind F3 (unpublished data). The
restricted expression of cell surface nucleolin and the cell-type
specificity of the expression may explain why some investiga-
tors have not been able to document the presence of nucleo-
lin at the cell surface (Yu et al., 1998). A similar explanation
may apply to the heterogeneity of the cell surface nucleolin
expression in the vasculature of tumors and matrigel plugs;
local variation in endothelial cell proliferation is likely to oc-
cur in angiogenic lesions in vivo.
F3-displaying phage selectively homes to tumor vascula-
ture in vivo, and fluorescein-tagged F3 also binds to and is
taken up by endothelial cells in tumor vasculature. However,
the peptide also spreads to tumor cells, and it appears in a few
individual nonvascular cells in the skin and the gut (Porkka
et al., 2002). Intravenously injected antinucleolin antibody
was only detected in angiogenic vessels of tumors as well as of
matrigel plugs. The restricted distribution of the antibody re-
sembles that of the phage, probably because the size of phage
and antibody limit their access to tissues, whereas the rela-
tively small molecular mass of the peptide conjugate (
 
 
 
5
kD) may permit wider distribution. Nonetheless, each of
these reagents demonstrates the specificity of cell surface nu-
cleolin for angiogenic vessels within the vasculature.
F3 is rich in basic amino acids and binds to cell surface
heparan sulfate. However, our demonstration that CHO
cells lacking heparan sulfate (and other glycosaminoglycans)
internalize F3 excludes a direct role of heparan sulfate as the
internalizing molecule. Indeed, binding and antibody inhi-
bition studies show that F3 internalization is mediated by
cell surface nucleolin. El-Sheikh et al. (2002) have described
a peptide from the heparin-binding domain of vascular en-
dothelial growth factor that selectively homes to tumor vas-
culature. The authors attributed the tumor homing to affin-
ity of the peptide for heparan sulfate. It will be interesting to
see whether this peptide might also bind to nucleolin.
The internalization of the F3 peptide and NCL3 antibody
may reflect a physiological function of cell surface nucleolin.
Midkine is a 13-kD cytokine that, like F3, contains a high
proportion of basic amino acids (Said et al., 2002). It plays a
role in neurite outgrowth and neuronal differentiation, and
its mRNA is up-regulated in several human carcinomas
(Tsutsui et al., 1993). The internalization of midkine by
cells has been reported to be nucleolin dependent (Said et
al., 2002), although lipoprotein receptor-related protein can
also serve as the internalizing receptor for midkine (Shibata
et al., 2002). The binding site for midkine in nucleolin has
been localized to the RGG domain of nucleolin (Said et al.,
2002), whereas our antibody inhibition results implicate the
domain rich in acidic amino acids as the binding site for F3.
Cell surface nucleolin may also be involved in the activities
of basic FGF, which has been shown to bind to nucleolin in
nuclear extracts (Bonnet et al., 1996). Thus, F3, midkine,
and possibly basic FGF, might be internalized by a nucleo-
lin-dependent mechanism, but distinct binding sites on nu-
cleolin may exist to mediate the uptake.
A highly basic peptide derived from the HIV Tat protein
also binds to cells and is internalized by them. The Tat pep-
tide allows internalization of conjugated proteins and is
commonly used as a cell-penetrating agent (Fawell et al.,
1994; Langel, 2002). It is unlikely that the Tat peptide
would use nucleolin for its internalization and nuclear trans-
port. First, the internalization of Tat is independent of the
cell type, even in vivo, whereas our results show that cell sur-
face nucleolin is limited, it is expressed in angiogenic endo-
thelium but not in the blood vessels in normal tissues. Sec-
ond, treatment of cells with heparinase to remove heparan
sulfates inhibits internalization of the Tat peptide (Suzuki et
al., 2002), whereas we found that lack of heparan sulfates
did not affect F3 uptake. Third, Tat internalization is inde-
pendent of temperature and does not require energy, and
several other cell-penetrating peptides are similar to Tat in
this regard (Langel, 2002). In contrast, F3 uptake is blocked
at 4
 
 
 
C (Porkka et al., 2002). Finally, our antibody inhibition
data also suggest that Tat peptide internalization is indepen-
dent of nucleolin because an antinucleolin antibody inhib-
ited the uptake of F3 but not of the Tat peptide.
Our laboratory has recently described yet another type of
a cell-penetrating peptide, LyP-1, which is also rich in basic
amino acids (Laakkonen et al., 2002). This peptide specifi-
cally homes to the endothelium of tumor lymphatics and the
tumor cells in certain, but not all, tumors. The internaliza-
tion of this peptide is not affected by antinucleolin antibod-
ies (unpublished data). Thus, several different internaliza-
tion mechanisms for basic peptides appear to exist, both
universal and cell-type specific.
Cell-penetrating peptides rich in basic amino acids are
transported into the nucleus after internalization (Langel,
2002). This is also the case with F3 and LyP-1 (Laakkonen
et al., 2002; Porkka et al., 2002). Nucleolin is thought to be
responsible for the nuclear transport of midkine (Shibata et
al., 2002), and the same may be the case with F3. It is also
possible that the multiple basic amino acids in F3 form one
or more independent nuclear localization signals.
The selective in vivo homing of the two nucleolin-binding
reagents, the F3 peptide and the NCL3 antibody, to angio-
genic blood vessels establishes cell surface nucleolin as a new
angiogenesis marker. Tumor blood vessels undergo angio-
genesis (Hanahan and Folkman, 1996) and have specific
markers in common with other angiogenic vessels (Ruo-
slahti, 2002). Future studies will determine whether cell sur-
face nucleolin might play a role in angiogenesis, possibly by
binding and internalizing growth factors such as midkine
and bFGF. The restricted expression of cell surface nucleolin
in angiogenic vessels and in tumor cells in vivo, and its abil-
ity to internalize molecules bound to it, make nucleolin an
attractive potential target for the development of agents for
vascular therapy of tumors.
 
Materials and methods
 
Cells and antibodies
 
MDA-MB-435 cells were grown in RPMI 1640 medium with 10% FCS and
1% Glutamine Pen-Strep (Irvine Scientific). CHO-K1 and pgsA-745 cells
were grown in 
 
 
 
MEM Earle’s salt with 10% FCS and 1% Glutamine Pen-
Strep. The antibodies used were mouse monoclonal antinucleolin (IgG
 
1
 
;
MS-3; Santa Cruz Biotechnology, Inc.) and rabbit polyclonal antibodies 
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raised against peptides synthesized according to the nucleolin sequence.
NCL2 and NCL3 were raised against amino acids 43–51 and 221–232 of
human nucleolin, respectively. The peptides were coupled to keyhole lim-
pet hemocyanin and used to immunize rabbits according to the manufac-
turer’s instructions. Antibodies were affinity purified from the sera on the
appropriate synthetic peptide immobilized on a SulfoLink Column (Pierce
Chemical Co.; 2 mg of peptide covalently coupled/column). Bound anti-
bodies were eluted with a glycine-hydrochloride buffer, pH 2.5, and neu-
tralized with 1 M Tris-HCl, pH 8. Each antibody immunoblotted the same
110-kD nucleolin band in cell extracts as the monoclonal antinucleolin.
 
F3 affinity chromatography and mass spectroscopy
 
Affinity purification of nucleolin from MDA-MB-435 detergent extracts
was performed as described previously (Christian et al., 2001b). In brief,
6 
 
 
 
 10
 
8
 
 cells were pelleted and lysed in 60 ml of RIPA buffer (1% Triton
X-100, 0.5% deoxycholic acid, 0.1% SDS, 10 mM Tris-HCl, pH 7.6, 150
mM NaCl, and 1% protease inhibitor cocktail for mammalian cells; Sigma-
Aldrich). The lysate was incubated with 20 
 
 
 
l F3 (AKVKDEPQRRSARL-
SAKPAPPKPEPKPKKAPAKK) affinity matrix (2 mg of peptide covalently
coupled to 1 ml of affigel 10). Control fractionation was performed on a
34–amino acid peptide that represents a scrambled version of F3. The ma-
trix beads were washed three times with 0.025% Triton X-100, 50 mM
Tris-HCl, pH 8.4, 150 mM NaCl, 1 mM CaCl
 
2
 
, and 0.02% azide; washed
twice with 25 mM Tris-HCl, pH 8.4, and 250 mM NaCl; and the bound
proteins were eluted with 30 
 
 
 
l SDS gel sample buffer. The affinity-puri-
fied proteins were reduced with 50 mM DTT and separated on an 8–20%
polyacrylamide gel and visualized by colloidal blue staining (Invitrogen).
The molecular masses of the gel bands were determined by comparing to
the standards in an Alphamanager instrument (Alpha Innotech Corp.).
Bands that appeared in the F3 eluate, but not in the control, were cut out,
digested with trypsin, and analyzed by mass spectroscopy using a matrix-
assisted laser desorption ionization, time of flight instrument (model Voy-
ager DE-PRO; Applied Biosystems) using an 
 
 
 
-cyano-4-hydroxycinnamic
acid/nitrocellulose matrix.
 
Immunoblot analysis
 
Cell extracts or affinity-purified samples were separated on an SDS-PAGE
and transferred onto nitrocellulose membranes for 1 h at 100 V. The mem-
branes were blocked overnight at 4
 
 
 
C with 5% milk powder in TBS-T (140
mM NaCl, 10 mM Tris-HCl, pH 7.4, and 0.05% Tween) and incubated
with mouse monoclonal or rabbit polyclonal antinucleolin antibody (10
 
 
 
g/ml in TBS-T) for 1 h at RT. After extensive washing, the membranes
were incubated with peroxidase-coupled rabbit anti–mouse or goat anti–
rabbit antibody, and bound antibody was detected with ECL (Amersham
Biosciences) and exposure to Biomax MR (Kodak).
 
Cell surface biotinylation
 
For cell surface expression analysis, MDA-MB-435 cells (5 
 
 
 
 10
 
6
 
 cells) were
washed three times with cold PBS on a cell culture plate and incubated with
biotinylation buffer (20 mM HEPES, pH 7.45, 5 mM KCl, 130 mM NaCl, 0.8
mM MgCl
 
2
 
, 1
 
 
 
mM CaCl
 
2
 
, and 0.5 mg/ml EZ link Sulfo-NHS-Biotin; Pierce
Chemical Co.) for 1 h at 4
 
 
 
C. After the removal of the reagent, the cells were
washed three times with wash buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1
mM MgCl
 
2
 
, and 1 mM CaCl
 
2
 
) and lysed in 1% Triton X-100 lysis buffer for
1 h. The lysates were centrifuged for 15 min at 15,000 
 
g
 
. F3 binding proteins
were isolated by affinity chromatography as described above, separated on
SDS-PAGE, and transferred to nitrocellulose. The nitrocellulose membranes
were incubated after blocking with ExtrAvidin–peroxidase conjugates di-
luted at 1:5,000 (Sigma-Aldrich) for 1 h at RT. Bands were detected after in-
cubation with ECL reagent and exposure to Biomax MR.
 
FACS analysis of cell surface nucleolin
 
For FACS
 
®
 
 analysis, MDA-MB-435 or HUVEC were detached with EDTA
and 10
 
6
 
 cells/sample were incubated with either polyclonal rabbit antinu-
cleolin antibody NCL3 (10 
 
 
 
g/ml) or monoclonal antinucleolin antibody
MS-3 (Santa Cruz Biotechnology, Inc.; 10 
 
 
 
g/ml) for 45 min on ice. Cells
were washed with ice-cold PBS and incubated with Alexa-488 (Molecular
Probes) secondary antibody (1:50 in PBS). As a negative control, the cells
were incubated with 10 
 
 
 
g/ml of rabbit IgG or with 10 
 
 
 
g/ml monoclonal
anti–c-myc antibody (Santa Cruz Biotechnology, Inc.), followed by the
secondary antibody. As a positive control, the cells were incubated with
10 
 
 
 
g/ml of mouse monoclonal anti–
 
 
 
3
 
-integrin (CBL 479; Cymbus Bio-
technology Ltd.). The antibody-treated cells were washed and resuspended
in 50 
 
 
 
l PBS containing 2 
 
 
 
g/ml propidium iodide to distinguish between
live and dead cells, and 10,000 cells per sample were analyzed using a
FACSCalibur flow cytometer.
 
Detection of peptides and antibodies in cells and tissues
 
For internalization experiments, cells were incubated with 1 
 
 
 
M of fluo-
rescein-conjugated peptide for 2 h at 37
 
 
 
C. The cells were washed with
PBS, fixed with 4% PFA in PBS, and analyzed by confocal microscopy.
The cell-penetrating basic peptide from the human immunodeficiency vi-
rus Tat protein (GRKKRRQRRR; Fawell et al., 1994) was used as a positive
control in the internalization experiments. To detect nucleolin, cells were
fixed with 4% PFA in PBS and stained with 10 
 
 
 
g/ml antinucleolin anti-
bodies either directly or after permeabilization with Triton X-100. Bound
antibodies were detected with Alexa-594–labeled anti–rabbit antibody
(Molecular Probes) and visualized by fluorescence microscopy.
In vivo distribution of circulation-accessible cell surface nucleolin was
examined in mice bearing xenograft tumors or basement membrane
(matrigel) plugs. Xenograft tumors were generated by subcutaneously in-
jecting exponentially growing MDA-MB-435 human breast cancer cells
(10
 
6
 
 cells in 200 
 
 
 
l of culture media) into the mammary fat pad area of
2-mo-old Balb/c 
 
nu/nu
 
 mice (Animal Technologies). The animals were used
for experiments 8 wk after injection. Nontumor angiogenesis was studied
in matrigel plugs (Fulgham et al., 1999; Ngo et al., 2000). 2-mo-old Balb/c
 
nu/nu
 
 mice were subcutaneously injected with 100 
 
 
 
l of Matrigel (Becton
Dickinson) at two or three locations in the abdominal area. Each 100-
 
 
 
l
plug contained 100 ng of recombinant human bFGF as an angiogenesis
stimulant (R&D Systems). The animals were used for antibody injection ex-
periments 8 d after the implantation.
In vivo distribution of antibodies was studied by intravenously injecting
mice with 200 
 
 
 
g of polyclonal rabbit antinucleolin antibody or rabbit
IgG. 1 h after the injection, the mice were anesthetized, perfused through
the heart with 10 ml PBS, and killed by infusing 10 ml of 4% PFA in PBS.
Tumors or matrigel plugs, along with various control tissues were removed,
fixed in 4% PFA, and frozen in OCT embedding medium (Tissue-Tek). All
procedures were performed under anesthesia induced by intraperitoneal
injection of 2,2,2-tribromoethanol (Avertin) at a dosage of 0.4–0.75 mg/
gram of body weight (500–700 
 
 
 
l/mouse). All animal experiments were ap-
proved by the Animal Review Committee of the Burnham Institute.
For histological analyses, 5-
 
 
 
m sections were cut. The injected rabbit
antinucleolin antibody and anti-CD31 antibody (10 
 
 
 
g/ml; BD Bio-
sciences) applied on the tissue sections were detected with Alexa-594–
and Alexa-488–conjugated secondary antibodies, respectively. The sec-
tions were examined under an inverted fluorescent microscope (Nikon) or
a confocal microscope (Bio-Rad Laboratories). Nuclei were counterstained
using DAPI (Vector Laboratories).
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